Last reviewed · How we verify

Renal function study — Treatment Landscape & Competitive Intelligence

Renal function study (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Renal function study, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
INULIN INULIN Iso Tex Non-Standardized Food Allergenic Extract [EPC] 1940-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Renal function study
  2. Iso Tex · 1 drug in Renal function study

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Renal function study:

Cite this brief

Drug Landscape (2026). Renal function study — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/renal-function-study. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing